Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Association Française Contre Les Myopathies – Afm-Téléthon has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner in 1 distinct art unit. HUTSON, RICHARD G is the busiest examiner with 1 pending action. This single examiner and art unit represent the current focus of the company's active patent prosecution. For a practitioner, this singular point of contact allows for a highly focused strategy tailored to one examiner's specific preferences.
The involvement of 1 distinct art unit suggests that the company's current biotechnology innovation falls into a specific technical category. Because the prosecution is limited to 1 distinct examiner, the outcome depends entirely on the interactions with HUTSON, RICHARD G. There is no need to manage multiple examiner styles or varying art unit standards. This 1 pending office action can be addressed with a clear understanding of the assigned examiner's specific requirements. The data shows a streamlined prosecution environment where the company's immediate pharmaceutical patent goals are tied to a single examination process, with no other active matters currently pending.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725699 | THERAPEUTICAL PEPTIDOMIMETIC | HUTSON, RICHARD G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725699 | THERAPEUTICAL PEPTIDOMIMETIC | HUTSON, RICHARD G | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725699 | THERAPEUTICAL PEPTIDOMIMETIC | HUTSON, RICHARD G | 1652 | §102§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAssociation Française Contre Les Myopathies – Afm-Téléthon has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Richard G Hutson has the most, with 1 of Association Française Contre Les Myopathies – Afm-Téléthon's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
